Positive in vivo efficacy and pharmacokinetic data shows AVA04-VbP drug conjugate out-performed Bavencio immunotherapy
Joint venture to develop next generation cell and gene therapies incorporating Affimer proteins
LG Chem selects second and third drug targets following rapid progress in first program
New collaboration to focus on developing potent Affimer-drug conjugates
Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumor indications as the basis of bispecific and combination therapies
Royalty-bearing license agreement to commercialize a product incorporating the Affimer technology
Drug conjugate combines Avacta’s Affimer technology with conjugates developed at Tufts for precision delivery
